Dr. Michael Salgaller leads the Technology Analysis and Marketing Unit (TAMU) within the NIH’s Technology Transfer Office, where he leverages over 20 years of business, scientific, and investment experience in various life science sectors to support technology development and commercialization. His unit serves a business development role to foster licensing and collaborative activity between buy-side stakeholders and the NIH. Immediately prior to returning to NIH, Michael was a Vice President at The Conafay Group, a healthcare-focused government affairs firm in downtown DC, where he led alliance development activities centered on civilian health. He served as President of Biologics Consulting Group, a boutique firm providing professional services focused on regulatory affairs. Michael spent several years on the investment team of an early-stage venture capital firm dedicated to the life sciences. He began his buy-side career as Vice President of R&D for Northwest Biotherapeutics. He began his scientific career as a Senior Scientist at the NIH – after starting his working career spending summers at the Pittsburgh Zoo feeding hot dogs to polar bears. He is the author of “Biotechnology Entrepreneurship,” and teaches an entrepreneurship class at NIH. He has written over 70 scientific/business articles and book chapters. Dr. Salgaller received his PhD in Pathology from The Ohio State University